The latest biotech news

News and Trends 25 Aug 2016

Daratumumab could Knock Multiple Myeloma Down and Out: EMA will Judge

Multiple Myeloma is almost a death sentence: you probably won’t make it through five more years, and even if current treatments send it to remission, your chances of relapse are high. Janssen’s new drug, Darzalex (daratumumab), has shown promise to knock MM down and out for good in Phase III trails, and it now awaits […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 25 Aug 2016

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis. Phase III trials have officially begun! Galapagos is making progress as its rheumatoid arthritis drug, filgotinib, enters Phase III clinical trials. This comes after a major setback when its deal with AbbVie fell through last fall. It’s not […]

August 25, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 24 Aug 2016

While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’

Despite progress in HIV treatments and towards an HIV cure, the infection rate has risen to unprecedented levels in Europe. Gilead’s HIV-1 ‘vaccine’, Truvada, has just been approved for marketing in Europe to stop its spread. The year 2014 brought the highest number of new HIV diagnoses ever recorded in Europe, 94% of which were […]

August 24, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 23 Aug 2016

€350M CRISPR Joint Venture now has a Name and an Office

Bayer and CRISPR Therapeutics have invested $373M in a joint venture, Casebia, as the latest effort to bring the revolutionary gene editing technology to the medical market. This brainchild represents a huge leap of faith, since no preliminary results have been revealed. The Boston launch may accelerate its progress through clinical trials and produce the first […]

August 23, 2016 - 3 minutesmins - By Evelyn Warner

sanofi novo nordisk diabetes insulin glp 1 agonist combination

News and Trends 22 Aug 2016

Sanofi loses lead on new Diabetes drug, because of… an user-unfriendly Pen

Sanofi and Novo Nordisk have been in a tight race to put their new insulin GLP-1 combination drugs for Type 2 Diabetes on the market. Sanofi now suffers a short (but critical) setback, as the FDA is not impressed with its drug delivery system. Sanofi and Novo Nordisk have both strong positions in the diabetes […]

August 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Aug 2016

This new vaccine could tackle both Zika and Dengue at once

These potentially fatal diseases have reached pandemic proportions and are starting to threaten the Western world. Excivion (UK) and Xenetic (US) have announced a partnership to develop a combined vaccine for Dengue and Zika Viruses using new vaccine delivery technology. Following on Sanofi’s initiatives to combat the spread of Zika and Dengue viruses, a transatlantic partnership between […]

August 22, 2016 - 2 minutesmins - By Evelyn Warner

sanofi biotech acquisition medivation msd

News and Trends 22 Aug 2016

UPDATE: Sanofi defeated in the Race to acquire Medivation

Even more Big Pharma join the fight to acquire the extremely desirable Medivation, a Biotech developing cancer treatments. Now MSD is joining the bandwagon. Things don’t look so good for Sanofi, which already got rebuffed twice. UPDATE (article originally published on 18/8/2016): Pfizer has struck a deal to acquire Medivation for $14Bn (€12.4Bn), according to the Financial Times. This was […]

August 22, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 22 Aug 2016

Now we can watch DNA Repair itself!

After 2015’s Nobel Prize in chemistry was awarded for advancements in our understanding of DNA repair, a recent Nature report characterises the mechanism in molecular detail. The implications for cancer research are vast. Researchers in Paris, France, and Bristol, England, have leveraged recent advances in microscopy and fluorescent imaging to characterise the entire process of DNA […]

August 22, 2016 - 2 minutesmins - By Evelyn Warner

News and Trends 20 Aug 2016

France is loving this Iranian Bioartist’s Microbe-Inspired Installations

Bioartist Golnaz Behrouznia creates gorgeous multimedia installations inspired by microscopic life. Keep an eye out for her work at festivals in Paris and Toulouse this September. Golnaz Behrouznia has always been passionate about natural science, particularly the world seen through a microscope. Through a combination of plastic sculpture, drawing, and installation video, she brings it […]

August 20, 2016 - 2 minutesmins - By Evelyn Warner

inotrem nancy france inflammation startup

News and Trends 19 Aug 2016

Inotrem on its way to Control Acute Inflammation

We leave the North of Spain, meander through the Pyrenees and prendons un verre du vin français before arriving in Nancy. Here, we can visit the city’s UNESCO World Heritage Site and have a good quiche Lorraine. Then, it’s time to head to Inotrem, our Biotech of the Week. City: Nancy, France Founded: 2013 Employees: 12 Financial Data: €18M […]

August 19, 2016 - 1 minutemin - By Denise Neves Gameiro

News and Trends 18 Aug 2016

Invidior approaches FDA Approval of Opioid Addiction Treatment

Invidior has revamped buprenorphine with a sustained release formulation known as RBP-6000 that shows promising results in Phase III clinical trials for the treatment of opioid addiction. The latest addiction treatment from Invidior, RBP-6000, has made considerable progress through Phase III clinical trials. At the core of RBP-6000 is the old drug, buprenorphine, but Invidior has […]

August 18, 2016 - 3 minutesmins - By Evelyn Warner

News and Trends 18 Aug 2016

This Icelandic Start-Up just raised Money to turn injections into Eye-Drops

Oculis just closed its Series A fundraising with the help of Icelandic investors. The money will help get its first eye-drops in the market, to treat diabetic macular edema (DME) without injections or implants. Based in Reykjavik, Oculis was founded in 2003 to develop a new drug delivery platform. This technology consists of solubilizing nanoparticles (SNP), which […]

August 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Daratumumab could Knock Multiple Myeloma Down and Out: EMA will Judge

Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis

While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’

€350M CRISPR Joint Venture now has a Name and an Office

Sanofi loses lead on new Diabetes drug, because of… an user-unfriendly Pen

This new vaccine could tackle both Zika and Dengue at once

UPDATE: Sanofi defeated in the Race to acquire Medivation

Now we can watch DNA Repair itself!

France is loving this Iranian Bioartist’s Microbe-Inspired Installations

Inotrem on its way to Control Acute Inflammation

Invidior approaches FDA Approval of Opioid Addiction Treatment

This Icelandic Start-Up just raised Money to turn injections into Eye-Drops

Subscribe to our newsletter to get the latest biotech news!